{"product_id":"teleflex-five-forces-analysis","title":"Teleflex Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTeleflex faces moderate supplier power but high buyer scrutiny and regulatory pressures, while rivalry from established medtech players keeps margins in check; threats from substitutes and new entrants are limited by clinical validation and IP. This snapshot highlights key competitive tensions and strategic levers for Teleflex. Unlock the full Porter's Five Forces Analysis to access force-by-force ratings, visuals, and actionable insights for investment or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Grade Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Teleflex devices needs highly specific polymers and metals meeting strict biocompatibility standards; only about 20–30 global suppliers hold FDA and ISO 13485 certifications for these materials, concentrating supply and giving them moderate bargaining power.\u003c\/p\u003e\n\u003cp\u003eBasic feedstock is abundant, but certified medical-grade inputs are limited, so supplier leverage can affect margins; industry reports show premium for certified materials of 10–25% vs commodity grades.\u003c\/p\u003e\n\u003cp\u003eTeleflex reduces risk with multi-year contracts and a diversified vendor base—in 2024 it reported sourcing from over 15 qualified suppliers and keeping strategic inventory equal to ~60 days of production to avoid single-source disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers must follow strict quality management systems aligned with Teleflex’s FDA-regulated requirements, including ISO 13485 and 21 CFR Part 820, raising supplier compliance costs often \u0026gt;$0.5–1.5M per product line for validation and documentation.\u003c\/p\u003e\n\u003cp\u003eSwitching suppliers is costly and slow: audits, process validation, and regulatory filings can take 6–18 months and cost millions, so qualified suppliers gain pricing leverage and firmer contract terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Global Supply Chain Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpfluctuations in energy costs and logistics container rates rose suppliers input prices which they often pass to device makers like teleflex tfx contributing a cogs pressure medical-supply peers during geopolitical shocks inflation u.s. cpi supplier pass-throughs tightened margins. buffers this via strategic inventory vendor contracts working-capital days varied smooth supply disruption.\u003e\n\u003c\/pfluctuations\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation Among Component Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe medical supply chain saw notable consolidation: between 2019–2024 roughly 120 smaller component suppliers were acquired by larger firms, raising supplier concentration in key device inputs by ~18% (source: industry M\u0026amp;A reports through 2024).\u003c\/p\u003e\n\u003cp\u003eAs concentration rose, large suppliers gained pricing leverage—average component price inflation for catheter-related parts hit 6.5% in 2023 vs 2.1% in 2019—stretching OEM margins.\u003c\/p\u003e\n\u003cp\u003eTeleflex must use its $2.4B 2024 revenue scale and global sourcing footprint to secure long-term contracts, dual sourcing, and volume discounts to counter supplier leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~120 acquisitions 2019–2024\u003c\/li\u003e\n\u003cli\u003eSupplier concentration +18%\u003c\/li\u003e\n\u003cli\u003eComponent price inflation 6.5% in 2023\u003c\/li\u003e\n\u003cli\u003eTeleflex revenue $2.4B (2024) — leverage point\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Uniqueness of Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCertain Teleflex products in interventional cardiology and vascular access use proprietary components; when a part is unique to a single supplier’s patented process, that supplier gains strong leverage over pricing and delivery. Teleflex counters this by co-developing tech and securing IP; in 2024 Teleflex invested roughly $145m in R\u0026amp;D (about 6.2% of revenue) to reduce supplier dependence. Here’s the quick math: single-source parts can raise input costs by 5–15%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-source patents → high supplier leverage\u003c\/li\u003e\n\u003cli\u003eCo-development and licensing reduce risk\u003c\/li\u003e\n\u003cli\u003e$145m R\u0026amp;D in 2024, 6.2% of revenue\u003c\/li\u003e\n\u003cli\u003eInput-cost markup risk ≈ 5–15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited FDA-certified suppliers drive 10–25% material premiums; Teleflex hedges with R\u0026amp;D, contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers of medical-grade polymers\/metals hold moderate-to-strong leverage due to limited FDA\/ISO 13485-certified sources (20–30 globally) and costly validation (\u0026gt;$0.5–1.5M), causing 10–25% premiums vs commodity inputs; Teleflex (revenue $2.4B in 2024) uses multi-year contracts, 15+ qualified suppliers, ~60 days inventory, $145M R\u0026amp;D to mitigate 5–15% single-source markups.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified suppliers\u003c\/td\u003e\n\u003ctd\u003e20–30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaterial premium\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation cost\u003c\/td\u003e\n\u003ctd\u003e$0.5–1.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeleflex revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$2.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$145M (6.2%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory buffer\u003c\/td\u003e\n\u003ctd\u003e~60 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Teleflex, this Porter's Five Forces analysis uncovers key drivers of competition, supplier and buyer power, entry barriers, substitutes, and disruptive threats shaping the company’s pricing power and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for Teleflex—quickly identify competitive pressures and prioritize strategic responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant share of teleflex product revenue per company filings via contracts with group purchasing organizations and integrated delivery networks which bundle thousands hospitals to demand deep volume discounts.\u003e\n\u003cpthis buyer concentration forces teleflex to accept lower list prices and tighter payment terms industry data show hospital gpo-negotiated discounts often exceed squeezing device makers gross margins.\u003e\n\u003c\/pthis\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift Toward Value-Based Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphealthcare purchasers now tie payments to outcomes and total cost of care not procedure count so hospitals demand evidence that teleflex devices cut readmissions or shorten stays cms private payers linked medicare value-based programs by buyers require peer-reviewed trials health-economic models showing cost-per-qaly improvements will reject innovations with higher prices but no proven savings. this raises price sensitivity extends purchase cycles as customers vet clinical economic data.\u003e\n\u003c\/phealthcare\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Commodity Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn segments such as basic respiratory care and standard urological supplies, products are treated as commodities with low clinical differentiation, so hospitals can switch brands with minimal training or disruption. That low switching cost makes price the main decision lever; Teleflex (NYSE: TFX) faces pressure to match competitive pricing in high-volume SKUs—its 2024 Consumable \u0026amp; Devices revenue of about $1.6B highlights the stakes. Aggressive cost competition erodes margins and forces volume-driven strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Price Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital procurement platforms and third-party data services have raised price transparency in medical devices; a 2024 Vizient report showed 68% of US hospitals use benchmarking tools to compare vendor prices, letting administrators compare Teleflex prices to Medtronic and Becton Dickinson in real time.\u003c\/p\u003e\n\u003cp\u003eThis transparency lowers manufacturers’ ability to maintain premiums unless Teleflex shows clear clinical or workflow differentiation; public hospital group purchasing savings averaged 12–18% in 2023 when switching vendors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% hospitals use benchmarking tools (Vizient, 2024)\u003c\/li\u003e\n\u003cli\u003eReal-time price comparisons vs Medtronic, Becton Dickinson\u003c\/li\u003e\n\u003cli\u003ePremium pricing erodes without clear product differentiation\u003c\/li\u003e\n\u003cli\u003eGPO-driven savings 12–18% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Third-Party Reimbursement Limits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealthcare providers—the ultimate customers—depend on reimbursement from Medicare, Medicaid, and private insurers; Medicare accounted for ~20% of US hospital revenue in 2023, so cuts bite quickly.\u003c\/p\u003e\n\u003cp\u003eWhen procedure reimbursements fall, hospitals press device suppliers like Teleflex for lower unit prices; Teleflex saw 2024 US sales exposure ~60% of revenue, so price demands materially affect margins.\u003c\/p\u003e\n\u003cp\u003eTeleflex’s pricing power is capped by reimbursement rates across markets; a 5% Medicare payment cut can force equivalent pricing concessions downstream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare ~20% hospital revenue (2023)\u003c\/li\u003e\n\u003cli\u003eTeleflex ~60% US exposure (2024)\u003c\/li\u003e\n\u003cli\u003e5% Medicare cut → ~5% supplier price pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Buyers, Benchmarking \u0026amp; Medicare Cap Teleflex’s Pricing Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpbuyer concentration via gpos of teleflex product revenue and benchmarking tools hospitals use them vizient forces deep discounts links pricing to outcomes hospital caps power us exposure in\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO\/IDN share\u003c\/td\u003e\n\u003ctd\u003e≈28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals using benchmarking\u003c\/td\u003e\n\u003ctd\u003e68% (Vizient, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO discounts\u003c\/td\u003e\n\u003ctd\u003e12–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare share\u003c\/td\u003e\n\u003ctd\u003e≈20% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeleflex US exposure\u003c\/td\u003e\n\u003ctd\u003e≈60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pbuyer\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eTeleflex Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Teleflex Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or samples—fully formatted and ready for download and use the moment you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747021828473,"sku":"teleflex-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/teleflex-five-forces-analysis.png?v=1772194387","url":"https:\/\/matrixbcg.com\/products\/teleflex-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}